WebDoctor Encyclopedia

Childhood Genitourinary

Primary mediastinal germ cell tumour

A primary mediastinal germ cell tumour grows in the front of the chest rather than in the testes or ovaries. Teratomas are cured by surgery, seminomas respond very well to chemotherapy, and non-seminomas need chemotherapy followed by surgery.

Medically reviewed Last reviewed October 21, 2026

What is a primary mediastinal germ cell tumour?

A primary mediastinal germ cell tumour is a growth made of germ cells, the cells that normally develop into sperm or eggs, which arises in the mediastinum. The mediastinum is the central part of the chest that lies between the lungs and contains the heart, the windpipe, the gullet and large blood vessels. Most of these tumours grow in the front (anterior) part of the mediastinum, just behind the breastbone.

Germ cell tumours usually start in the testes or ovaries. Occasionally they appear elsewhere along the midline of the body, for example in the chest, at the back of the abdomen or in the brain. Experts believe this happens because some germ cells stray from their normal path while the embryo is developing and settle in the wrong place (El-Zaatari and Ro, 2021). When a germ cell tumour arises outside the gonads, the chest is the most common site.

These tumours mostly affect young men, typically in their 20s and 30s. They range from benign mature teratomas, which are cured by surgery alone, to aggressive non-seminomatous cancers. Treatment for the malignant forms combines chemotherapy and surgery, and many patients are cured. However, the non-seminoma group has the poorest outlook of all germ cell tumours (Ozgun and Nappi, 2023).

This article explains the different types, how they are diagnosed and treated, and what to expect afterwards.

1. Key facts at a glance

Feature Details
Where it grows Anterior mediastinum, behind the breastbone
Who is affected Mainly young men; mean age around 29 years in a large surgical series
Main groups Teratoma, seminoma, non-seminomatous germ cell tumour
Genetic hallmark Extra copies of chromosome 12p, often as isochromosome 12p
Linked conditions Klinefelter syndrome
Blood tumour markers AFP, beta-hCG and LDH
Main treatment Chemotherapy, then surgery to remove remaining tumour
Benign teratoma Surgery alone
Outlook Good for seminoma; poorer for non-seminoma

2. Types

Mediastinal germ cell tumours are classified in the same way as testicular germ cell tumours (El-Zaatari and Ro, 2021).

Type Description Typical behaviour
Mature teratoma Contains well-formed tissues such as skin, hair, fat and teeth Benign; cured by removal
Immature teratoma Contains embryonic-looking tissue Behaviour depends on the amount of immature tissue
Seminoma Pure seminoma Very sensitive to chemotherapy; survival similar to testicular seminoma
Yolk sac tumour Often produces AFP Aggressive
Embryonal carcinoma Primitive cells Aggressive
Choriocarcinoma Produces high beta-hCG Aggressive; tends to spread through the blood
Mixed germ cell tumour Combination of the above Treated as non-seminoma

Seminoma versus non-seminoma

Feature Seminoma Non-seminoma
AFP level Normal Often raised
Beta-hCG level Normal or mildly raised May be high
Response to chemotherapy Excellent Good, but residual masses are common
Need for surgery after chemotherapy Less often Usually
IGCCCG risk group Good or intermediate Poor risk by definition

Non-seminomas of the mediastinum are placed in the poor-risk group of the International Germ Cell Cancer Collaborative Group (IGCCCG) whatever their marker levels (Rosti et al., 2019).

Other cancers that can develop

Rarely, a mediastinal germ cell tumour gives rise to a different kind of cancer, such as a sarcoma or carcinoma within a teratoma (somatic-type malignancy). A blood cancer, such as leukaemia, can also occur in association with these tumours (El-Zaatari and Ro, 2021). Such complications are uncommon but affect treatment and outlook.

3. Causes and risk factors

Risk factor Notes
Male sex Malignant forms occur mostly in men
Young adult age Peak in the third and fourth decades
Klinefelter syndrome A chromosomal condition (47,XXY) linked with a higher risk
Abnormal germ cell migration Thought to underlie all extragonadal germ cell tumours

Most people with this tumour have no known risk factor. It is not caused by lifestyle and is not passed on in families in most cases. Doctors will usually examine the testes and arrange an ultrasound, because a testicular primary that has spread to the chest must be ruled out.

4. How does it look

On scans

Test Typical findings
Chest X-ray A widened central shadow in the chest
CT of the chest A large mass in the front of the chest
Mature teratoma on CT Mixture of fat, fluid and calcium, sometimes teeth
Seminoma on CT A fairly uniform solid mass
Non-seminoma on CT Irregular mass with areas of bleeding or dead tissue; may invade nearby structures
PET-CT Useful in seminoma after chemotherapy
Testicular ultrasound Excludes a primary tumour in the testis

Under the microscope

Feature What the pathologist looks for
Cell pattern Identifies seminoma, yolk sac tumour, embryonal carcinoma, choriocarcinoma or teratoma
Immunostains Markers such as SALL4, OCT3/4, CD117, glypican-3 and CD30 help separate the types
12p status Confirms germ cell origin when the pattern is unusual
Somatic elements Detects sarcoma or carcinoma within a teratoma

5. Symptoms

Small tumours may cause no symptoms and be found on a chest X-ray done for another reason. Larger tumours press on structures in the chest.

Common symptoms

  • Chest pain or a feeling of pressure
  • Cough
  • Breathlessness
  • Fever, night sweats or weight loss

Less common symptoms

Symptom Possible cause
Swelling of the face, neck and arms Pressure on the superior vena cava (SVC obstruction)
Hoarse voice Pressure on the nerve to the voice box
Coughing up blood Invasion of the airway or lung
Breast enlargement in men High beta-hCG levels
Coughing up hair or fatty material A teratoma that has opened into the airway (rare)

When to seek urgent help

Get urgent medical help if you notice sudden swelling of the face or neck, severe breathlessness, or difficulty breathing when lying flat.

6. Diagnosis

Test Purpose
CT of the chest, abdomen and pelvis Size of the mass and spread
Blood tumour markers (AFP, beta-hCG, LDH) Help with diagnosis, risk grouping and monitoring
Biopsy Usually a needle biopsy guided by CT
Testicular examination and ultrasound Rules out a testicular primary
MRI of the brain If symptoms suggest brain spread or markers are very high
Lung function tests Before chemotherapy and surgery
Chromosome test When Klinefelter syndrome is suspected
Sperm banking Offered before chemotherapy

In some very urgent situations, with very high markers and a typical scan, doctors may start chemotherapy before a biopsy is taken.

Risk grouping

IGCCCG group Mediastinal seminoma Mediastinal non-seminoma
Good risk No spread to organs other than the lungs Not applicable
Intermediate risk Spread to organs other than the lungs Not applicable
Poor risk Not applicable All cases

7. Treatment

Because the disease is rare, there are no prospective trials comparing treatments, and patients are treated using the general principles for germ cell tumours (Rosti et al., 2019). Care should be given in a centre with germ cell tumour expertise.

Treatment by tumour type

Tumour type Usual approach
Mature teratoma Surgical removal alone, without chemotherapy
Seminoma Cisplatin-based chemotherapy; surgery or radiotherapy is rarely needed
Non-seminoma Cisplatin-based chemotherapy, then surgery to remove any remaining mass
Somatic-type malignancy Surgery, plus treatment directed at the specific cancer type

Chemotherapy

Regimen Notes
BEP (bleomycin, etoposide, cisplatin) Standard for many germ cell tumours
VIP (etoposide, ifosfamide, cisplatin) Often preferred for mediastinal non-seminoma because it avoids bleomycin
EP (etoposide, cisplatin) An option for some seminomas
High-dose chemotherapy with stem cell rescue Used in some relapsed cases

Bleomycin can damage the lungs. In one centre’s series of 255 operated patients, serious lung injury after surgery (acute respiratory distress syndrome) occurred in about 1 in 9 and was considerably more frequent after bleomycin-containing treatment (Kesler et al., 2021). The authors recommend avoiding bleomycin before chest surgery.

Surgery after chemotherapy

After chemotherapy, the blood markers usually fall, but a mass often remains. Surgeons remove this residual mass, typically through a sternotomy (an incision through the breastbone) or a clamshell incision. The operation may involve removing part of a lung, the pericardium or large blood vessels.

What is found in the remaining mass Share in the Kesler series Meaning
Dead tissue (necrosis) only About 25% Best outlook
Teratoma About 34% Removal is essential, as teratoma does not respond to chemotherapy
Active cancer About 40% Poorer outlook; further treatment may be needed

Treatment timeline for non-seminoma

Phase What happens Typical length
Diagnosis and staging Scans, markers, biopsy, sperm banking 1-2 weeks
Chemotherapy Usually four cycles, each lasting three weeks About 3 months
Recovery and re-staging Repeat scans and markers 3-6 weeks
Surgery Removal of the remaining mass Hospital stay of about a week
Further treatment if needed More chemotherapy if active cancer remains Varies

Side effects

Treatment Possible side effects
Chemotherapy Tiredness, infection risk, nausea, hair loss, hearing loss, tingling in hands and feet, kidney effects, reduced fertility
Bleomycin Lung scarring
Ifosfamide Bladder irritation, confusion, kidney effects
Chest surgery Pain, breathing problems, bleeding, nerve injury affecting the voice or diaphragm

8. Outlook (prognosis)

Factor Effect
Seminoma Outlook similar to testicular seminoma
Non-seminoma The poorest survival of all germ cell tumour presentations
Choriocarcinoma before chemotherapy Linked with worse survival
Seminoma elements in a non-seminoma Linked with better survival
Necrosis only in the residual mass Better survival
Active cancer in more than half the residual mass Roughly doubled risk of death
Raised markers after surgery Strong predictor of poorer survival

The figures come from Ozgun and Nappi (2023) and Kesler et al. (2021). Better treatments for non-seminoma, both first-line and at relapse, are still needed (Ozgun and Nappi, 2023).

9. Follow-up

Time after treatment Typical checks
Years 1-2 Clinic visit and tumour markers every 1-3 months; chest imaging every 3-6 months
Years 3-5 Visits and markers every 4-6 months; imaging less often
After 5 years Yearly review, including long-term effects

Long-term effects to monitor

Effect What to watch for
Hearing loss and tinnitus Hearing tests if symptoms appear
Nerve damage Numbness or tingling
Heart and blood vessel risk Blood pressure, cholesterol and weight checks
Low testosterone Tiredness, low mood, low libido
Second cancers, including blood cancers Regular blood counts

10. Living with a mediastinal germ cell tumour

  • Bank sperm before chemotherapy if you may want children
  • Tell doctors about bleomycin before any future anaesthetic, as high oxygen levels can harm lungs exposed to it
  • Stop smoking to protect your lungs and heart
  • Build up activity gradually after chest surgery, with physiotherapy if offered
  • Keep follow-up appointments, as relapse is most likely in the first two years
  • Look after your heart health with exercise and a balanced diet
  • Seek support from testicular and germ cell cancer charities

11. Frequently asked questions

Question Answer
Is it testicular cancer? No, it starts in the chest, but it is related and treated in a similar way
Is a teratoma cancer? A mature teratoma is benign and is cured by surgery
Why do I need surgery after chemotherapy worked? The leftover mass may contain teratoma or active cancer
Why are my blood markers checked so often? Rising AFP or beta-hCG is an early sign of relapse
Can women get it? Yes, but malignant forms are much more common in men
Will I be able to have children? Many men father children; sperm banking is advised
Can it come back? Yes, most often within two years

12. Questions to ask your care team

  • Is my tumour a teratoma, seminoma or non-seminoma?
  • What are my tumour marker levels, and what is my risk group?
  • Which chemotherapy do you recommend, and will it include bleomycin?
  • Will I need surgery, and what will it involve?
  • How can I protect my fertility?
  • Should I be tested for Klinefelter syndrome?
  • What follow-up will I have?

Resources

  1. El-Zaatari, Z.M. and Ro, J.Y. (2021) ‘Mediastinal germ cell tumors: a review and update on pathologic, clinical, and molecular features’, Advances in Anatomic Pathology, 28(5), pp. 335-350.
  2. Kesler, K.A. et al. (2021) ‘Outcomes following surgery for primary mediastinal nonseminomatous germ cell tumors in the cisplatin era’, Journal of Thoracic and Cardiovascular Surgery, 161(6), pp. 1947-1959.e1.
  3. Ozgun, G. and Nappi, L. (2023) ‘Primary mediastinal germ cell tumors: a thorough literature review’, Biomedicines, 11(2), 487.
  4. Rosti, G. et al. (2019) ‘Primary mediastinal germ cell tumors’, Seminars in Oncology, 46(2), pp. 107-111.
  5. National Cancer Institute (2026) Testicular Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/testicular/hp/testicular-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.